Jaguar Health (JAGX) & Eiger Biopharmaceuticals (NASDAQ:EIGR) Head to Head Comparison

Eiger Biopharmaceuticals (NASDAQ: EIGR) and Jaguar Health (NASDAQ:JAGX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, dividends and analyst recommendations.

Institutional and Insider Ownership

61.6% of Eiger Biopharmaceuticals shares are owned by institutional investors. Comparatively, 11.7% of Jaguar Health shares are owned by institutional investors. 28.8% of Eiger Biopharmaceuticals shares are owned by company insiders. Comparatively, 3.3% of Jaguar Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Eiger Biopharmaceuticals and Jaguar Health, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eiger Biopharmaceuticals 0 0 7 0 3.00
Jaguar Health 0 0 2 0 3.00

Eiger Biopharmaceuticals currently has a consensus target price of $29.00, indicating a potential upside of 233.33%. Jaguar Health has a consensus target price of $2.00, indicating a potential upside of 1,328.57%. Given Jaguar Health’s higher possible upside, analysts clearly believe Jaguar Health is more favorable than Eiger Biopharmaceuticals.

Profitability

This table compares Eiger Biopharmaceuticals and Jaguar Health’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Eiger Biopharmaceuticals N/A -169.16% -95.71%
Jaguar Health -190.94% -17.50% -4.11%

Valuation & Earnings

This table compares Eiger Biopharmaceuticals and Jaguar Health’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Eiger Biopharmaceuticals N/A N/A -$47.08 million ($5.30) -1.64
Jaguar Health $140,000.00 90.83 -$14.73 million ($0.67) -0.21

Jaguar Health has higher revenue and earnings than Eiger Biopharmaceuticals. Eiger Biopharmaceuticals is trading at a lower price-to-earnings ratio than Jaguar Health, indicating that it is currently the more affordable of the two stocks.

Summary

Jaguar Health beats Eiger Biopharmaceuticals on 7 of the 11 factors compared between the two stocks.

Eiger Biopharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema. Lonafarnib is an orally active inhibitor of farnesyl transferase that inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. It is conducting over three Phase II clinical trials, which include LOnafarnib With and without Ritonavir (LOWR) HDV-2 (Ankara, Turkey), LOWR HDV-3 (NIH) and LOWR HDV-4 (Hannover, Germany). Exendin is in Phase II clinical studies for the treatment of hypoglycemia associated with bariatric surgery. Ubenimex is in Phase II clinical studies for the treatment of PAH and lymphedema.

Jaguar Health Company Profile

Jaguar Health, Inc., formerly Jaguar Animal Health, Inc., is a natural-products pharmaceuticals company. The Company is focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. The Company, through its subsidiary Napo Pharmaceuticals, Inc., is focused on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its Mytesi is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with human immunodeficiency virus HIV/ acquired immune deficiency syndrome (AIDS) on antiretroviral therapy. Its other products include Canalevia, Equilevia, Neonorm Calf and Neonorm Foal.

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply